A missed shot: The failure of HPV vaccination state requirements

November 1, 2007

In an article appearing in the current issue of Clinical Pharmacology & Therapeutics, experts from the University of Pennsylvania Center for Bioethics and Johns Hopkins Berman Institute of Bioethics review the controversy surrounding the human papillomavirus (HPV) vaccine debate, and its effects on ethical and public health issues.

“The arrival of Gardasil® was a major achievement for cervical cancer prevention efforts worldwide,” says Jason Schwartz, MBE, Researcher, Penn’s Center for Bioethics and Department of History & Sociology of Science, and lead author. “Much of the initial enthusiasm for the vaccine was lost amid the controversy surrounding state proposals that would require teenage girls to be vaccinated in order to attend school. The events of the past year reveal important lessons regarding ways to introduce new vaccines successfully and in an ethically responsible manner."

In the months leading up to the June 2006 approval of Gardasil®, there was unprecedented media coverage and support from even socially-conservative groups. However, this support for the vaccine began to slow in September 2006 following the introduction of a bill in the Michigan state legislature that would require the vaccination of girls attending public schools. Additional states also were quick to propose similar legislation. In response to the legislation, numerous groups expressed their opposition by arguing that it was either too soon to consider an HPV requirement, or that the sexual transmission of the virus did not warrant requiring the vaccine in schools.

The opposition grew when the governor of Texas issued an executive order requiring HPV vaccination for all girls entering the sixth grade. Critics of state HPV requirements called attention to how these policies violated obligations to respect parental autonomy. However, many critics often overlooked opt-out provisions, implying that the proposals made vaccination compulsory.

The authors note that, “Quite apart from whether it was prudent public health policy to implement state requirements for HPV vaccination so soon after the vaccine’s licensure, these attacks on the state initiatives may have exacted a very real ethical price in terms of the public’s understanding of the justifications for state vaccination requirements generally, as well as the public’s understanding of the merits of the HPV vaccine itself.” Additionally, they suggest that issues of price gouging, corporate profits, and political motives, may have also added to the opposition.

In order to move forward with cervical cancer prevention efforts, the authors suggest that attention be focused on assessing the long-term safety of the vaccine, while implementing effective patient and provider educational programs about HPV and the HPV vaccine, as this is the model that other successful vaccination programs have followed. "With a second HPV vaccine expected to be approved in early 2008, it is vital to understand the strategies that are most likely to lead to the long-term success of this remarkable weapon against cervical cancer," says Schwartz.

The authors also discuss the importance of designing and implementing HPV vaccination programs in developing countries. "Cervical cancer is a worldwide concern, but its impact is particularly severe in the developing world,” says Schwartz. “It would be tragic if the negative attention created by the debate over HPV vaccine ‘mandates’ in the U.S. hamper efforts to make the vaccine available to those internationally who could benefit most from it."

Additional article authors are Arthur Caplan, PhD, Director, Center for Bioethics, Penn; Ruth Faden, PhD, MPH, the Philip Franklin Wagley Professor of Biomedical Ethics and Executive Director of The Phoebe R. Berman Bioethics Institute, Johns Hopkins University; and Jeremy Sugarman, MD, MPH, MA, the Harvey M. Meyerhoff Chair of Bioethics and Medicine at the Phoebe R. Berman Bioethics Institute, Johns Hopkins University

Source: University of Pennsylvania School of Medicine

Explore further: HPV vaccine tied to reduced respiratory papillomatosis rate

Related Stories

HPV vaccine tied to reduced respiratory papillomatosis rate

November 16, 2017
(HealthDay)—The incidence of juvenile-onset recurrent respiratory papillomatosis (JORRP) in Australia decreased from 2012 to 2016 after implementation of a quadrivalent human papillomavirus (HPV) vaccination program for ...

For college men, low awareness of HPV risk—Education may help increase vaccination rate

October 26, 2017
Male collegiate athletes have high rates of risk factors for infection with the cancer-causing human papillomavirus (HPV), but have low HPV vaccination rates and low awareness of their personal health risks, according to ...

HPV vaccine linked to drop in cases of rare childhood disease

November 9, 2017
(HealthDay)—The human papillomavirus (HPV) vaccine, first developed to help guard against cervical cancer, also seems to protect against a rare, chronic childhood respiratory disease, a new study suggests.

HPV vaccination and test reduce cancer risk by more than 90%

October 30, 2017
Every year there are around 400 new cases of cervical cancer and a total of approximately 800 cancers associated with HPV (human papilloma virus). Two measures could reverse this trend: the nonavalent HPV vaccination co-developed ...

HPV jab means women only need 3 cervical screens in a lifetime

November 10, 2017
Women may only need three cervical screens in their lifetime if they have been given the human papillomavirus (HPV) vaccine, according to a new study published in the International Journal of Cancer today (Friday).

HPV testing is better than the Pap test at detecting cervical cancer

November 14, 2017
A new paper in the Journal of the National Cancer Institute finds that testing for cervical cancer using HPV testing in addition to the Pap smear is unlikely to detect cancer cases that wouldn't be found using HPV testing ...

Recommended for you

Baby-boomers and millennials more afflicted by the opioid epidemic

November 21, 2017
Baby-boomers, those born between 1947 and 1964, experienced an excess risk of prescription opioid overdose death and heroin overdose death, according to latest research at Columbia University's Mailman School of Public Health. ...

Sensor-equipped pill raises technological, ethical questions

November 17, 2017
The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients ...

New painkillers reduce overdose risk

November 16, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed new opioid pain relievers that reduce pain on par with morphine but do not slow or stop breathing—the cause of opiate overdose.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.

Introduction is different, but top medications for opioid addiction equally effective

November 14, 2017
With opioid addiction officially declared a public health emergency in the U.S., medical intervention to treat the illness is increasingly important in responding to the epidemic. Now, a new study concludes that two of the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.